Fig. 1From: Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention studyChange in flow-mediated vasodilation (FMD) from baseline to study end. Change in flow-mediated vasodilation (FMD) (%) from baseline to study end in patients with inflammatory joint diseases and established atherosclerosis (n = 85) after 18 months of rosuvastatin treatment. FMD flow-mediated vasodilation, SE standard error, SD standard deviationBack to article page